Скачать или смотреть Emyria (ASX:EMD) - Broker Briefing Biotech & Nutrition Investor Webinar - March 2023

For the Broker Briefing March 2023 Biotech & Nutrition Investor Webinar, Emyria (ASX:EMD) Managing Director, Dr Michael Winlo, provides an overview oF EMD-RX5, the company's Cannabinoid capsule which is currently in Phase 3 Clinical Trials with global over the counter opportunity, and also discusses MDMA development for assisted therapy as well as newsflow catalysts going forward.

About Emyria

Emyria Limited (ASX:EMD) is a clinical drug development and care delivery company focused on accelerating drug development and improving patient outcomes in neuroscience and mental health via:

• Drug Development: Multiple, proprietary, Ultra-Pure cannabinoid dose forms suitable for registration against multiple indications. Emyria’s first dose form, EMD-RX5, is in Phase 3 trials.
• New Drug Discovery: Inspired by MDMA, Emyria is developing one of the world’s largest libraries of MDMA-like compounds with partner, the University of Western Australia.
• Proprietary Real-World Data (RWD): Emyria gathers robust and ethically-sourced data with patients cared for at Emyria’s own specialist clinical service (Emerald Clinics). Emyria RWD can help support drug development and care model improvement.